BR112017007144A2 - ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. - Google Patents
ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.Info
- Publication number
- BR112017007144A2 BR112017007144A2 BR112017007144A BR112017007144A BR112017007144A2 BR 112017007144 A2 BR112017007144 A2 BR 112017007144A2 BR 112017007144 A BR112017007144 A BR 112017007144A BR 112017007144 A BR112017007144 A BR 112017007144A BR 112017007144 A2 BR112017007144 A2 BR 112017007144A2
- Authority
- BR
- Brazil
- Prior art keywords
- composition
- compound
- pharmaceutically acceptable
- acceptable salt
- valproic acid
- Prior art date
Links
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 title abstract 3
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 title abstract 3
- 229960000604 valproic acid Drugs 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title 2
- -1 and Chemical class 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000011282 treatment Methods 0.000 abstract 3
- 102000009123 Fibrin Human genes 0.000 abstract 1
- 108010073385 Fibrin Proteins 0.000 abstract 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 230000008021 deposition Effects 0.000 abstract 1
- 229950003499 fibrin Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
a presente invenção se refere a ácido valproico, ou um sal farmaceuticamente aceitável do mesmo, para uso no tratamento ou na prevenção de uma afecção patológica associada ao excesso de deposição de fibrina e/ou formação de trombo, em que o dito tratamento compreende tratar um paciente com ácido valproico, ou um sal farmaceuticamente aceitável do mesmo, de uma maneira específica, e formulações para uso ou projetadas para uso em tais tratamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1417828.9A GB201417828D0 (en) | 2014-10-08 | 2014-10-08 | New methods and compositions |
PCT/GB2015/052950 WO2016055797A2 (en) | 2014-10-08 | 2015-10-08 | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112017007144A2 true BR112017007144A2 (pt) | 2017-12-19 |
Family
ID=51947070
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112017007144A BR112017007144A2 (pt) | 2014-10-08 | 2015-10-08 | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. |
Country Status (21)
Country | Link |
---|---|
US (3) | US10111845B2 (pt) |
EP (2) | EP3203997B1 (pt) |
JP (2) | JP6787901B2 (pt) |
KR (1) | KR20170063857A (pt) |
CN (3) | CN115721635A (pt) |
AU (1) | AU2015329795B2 (pt) |
BR (1) | BR112017007144A2 (pt) |
CA (2) | CA3234641A1 (pt) |
CL (1) | CL2017000866A1 (pt) |
DK (1) | DK3203997T3 (pt) |
ES (1) | ES2913225T3 (pt) |
GB (1) | GB201417828D0 (pt) |
HU (1) | HUE058316T2 (pt) |
IL (1) | IL251142B (pt) |
MX (2) | MX2017004558A (pt) |
MY (1) | MY192055A (pt) |
NZ (1) | NZ730307A (pt) |
PL (1) | PL3203997T3 (pt) |
RU (1) | RU2732761C2 (pt) |
SG (1) | SG11201702058XA (pt) |
WO (1) | WO2016055797A2 (pt) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG10201806849WA (en) | 2014-02-13 | 2018-09-27 | Incyte Corp | Cyclopropylamines as lsd1 inhibitors |
TWI664164B (zh) | 2014-02-13 | 2019-07-01 | 美商英塞特控股公司 | 作為lsd1抑制劑之環丙胺 |
WO2015123437A1 (en) | 2014-02-13 | 2015-08-20 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為lsd1抑制劑之咪唑并吡啶及咪唑并吡嗪 |
US9695180B2 (en) | 2014-07-10 | 2017-07-04 | Incyte Corporation | Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors |
WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
JP6995623B2 (ja) | 2015-04-03 | 2022-01-14 | インサイト・コーポレイション | Lsd1阻害剤としてのヘテロ環式化合物 |
TWI765860B (zh) | 2015-08-12 | 2022-06-01 | 美商英塞特公司 | Lsd1抑制劑之鹽 |
US20200179381A1 (en) * | 2016-04-08 | 2020-06-11 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
CN109414423A (zh) * | 2016-04-08 | 2019-03-01 | 赛伦诺科技有限公司 | 包含丙戊酸的延迟释放药物制剂和其用途 |
US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
US20230069590A1 (en) * | 2020-01-16 | 2023-03-02 | The Regents Of The University Of Michigan | Concentrated sodium valproate for rapid delivery |
CN111450072B (zh) * | 2020-05-07 | 2022-07-15 | 江苏艾立康医药科技有限公司 | 一种替格瑞洛控释片及其制备方法 |
GB2613900B (en) * | 2021-12-20 | 2024-01-17 | Cereno Scient Ab | Novel compounds and methods of use thereof |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4356108A (en) | 1979-12-20 | 1982-10-26 | The Mead Corporation | Encapsulation process |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
DE3773926D1 (de) | 1987-07-22 | 1991-11-21 | Farvalsa Ag | Feuchtigkeitsstabile feste valproinsaeure-zubereitung und verfahren zu ihrer herstellung. |
SE9402431D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New tablet formulation |
SE9402422D0 (sv) | 1994-07-08 | 1994-07-08 | Astra Ab | New beads for controlled release and a pharmaceutical preparation containing the same |
US6713086B2 (en) * | 1998-12-18 | 2004-03-30 | Abbott Laboratories | Controlled release formulation of divalproex sodium |
NZ511900A (en) | 1999-09-30 | 2003-06-30 | Penwest Pharmaceuticals Co | Sustained release matrix systems for highly soluble drugs |
AT408718B (de) | 1999-12-02 | 2002-02-25 | Gerot Pharmazeutika | Natriumvalproat-granulat mit verringerter hygroskopizität |
AU2002243231A1 (en) | 2000-11-21 | 2002-07-24 | Wake Forest University | Method of treating autoimmune diseases |
ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
US7090858B2 (en) | 2001-08-09 | 2006-08-15 | Swaminathan Jayaraman | Coated filter bag material for oral administration of medicament in liquid and methods of making same |
JP2006507297A (ja) | 2002-05-13 | 2006-03-02 | チルドレンズ・ホスピタル・ロサンジェルス | ケロイドおよび他の皮膚または内部創傷または病変における異常瘢痕形成の処置および予防 |
US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
US20040224006A1 (en) * | 2003-04-21 | 2004-11-11 | Samn Raffaniello | Ancrod irradiated, impregnated or coated sutures and other first aid or wound management bandaging materials for minimizing scarring and/or preventing excessive scar formation |
ITMI20040876A1 (it) | 2004-04-30 | 2004-07-30 | Univ Degli Studi Milano | Inibitori delle istone deacetilasi-hdac-quali agenti ipolipidemizzati per la terapia e la prevenzione dell'arteriosclerosi e malattie cardiovascolari |
PT1591109E (pt) | 2004-04-30 | 2008-09-05 | Desitin Arzneimittel Gmbh | Formulação exibindo libertação bifásica compreendendo um inibidor da desacetilase de histona |
US7713550B2 (en) * | 2004-06-15 | 2010-05-11 | Andrx Corporation | Controlled release sodium valproate formulation |
WO2006117165A2 (en) | 2005-05-02 | 2006-11-09 | Friedrich-Alexander-Universität Erlangen-Nürnberg | Means and methods for the treatment of head injuries and stroke |
EP1743654A1 (en) | 2005-07-15 | 2007-01-17 | TopoTarget Germany AG | Use of inhibitors of histone deacetylases in combination with NSAID for the therapy of cancer and/or inflammatory diseases |
AU2006287378A1 (en) | 2005-09-07 | 2007-03-15 | Braincells, Inc. | Modulation of neurogenesis by HDac inhibition |
EP1937650B1 (en) | 2005-09-08 | 2011-06-15 | S*BIO Pte Ltd | Heterocyclic compounds |
EP1815850B1 (en) | 2006-01-11 | 2008-11-26 | Teva Pharmaceutical Industries Ltd. | Controlled release formulation of divalproic acid and its derivatives |
US20100061984A1 (en) | 2006-01-20 | 2010-03-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
AU2007234380A1 (en) | 2006-04-06 | 2007-10-11 | Novartis Ag | Combination of organic compounds |
MX2009002166A (es) | 2006-08-31 | 2009-03-12 | Eurand Inc | Sistema de distribucion de farmacos, que comprenden soluciones solidas de farmacos debilmente basicos. |
GB2454118B (en) | 2007-06-06 | 2010-06-02 | Univ Maryland | Hdac inhibitors and hormone targeted drugs for the treatment of cancer |
US20090270497A1 (en) | 2008-04-24 | 2009-10-29 | Pharmacyclics, Inc. | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors |
GB201003766D0 (en) * | 2010-03-05 | 2010-04-21 | Univ Strathclyde | Pulsatile drug release |
US20110245154A1 (en) | 2010-03-11 | 2011-10-06 | Hemaquest Pharmaceuticals, Inc. | Methods and Compositions for Treating Viral or Virally-Induced Conditions |
CN101947209B (zh) | 2010-07-21 | 2012-07-25 | 河南中帅医药科技发展有限公司 | 双丙戊酸钠小丸及其制备方法 |
CN110063951A (zh) * | 2011-03-09 | 2019-07-30 | 赛伦诺科学有限公司 | 利用组蛋白脱乙酰酶抑制物改善受损的内源纤维蛋白溶解作用的化合物和方法 |
GB201417828D0 (en) | 2014-10-08 | 2014-11-19 | Cereno Scient Ab | New methods and compositions |
US20200179381A1 (en) | 2016-04-08 | 2020-06-11 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
CN109414423A (zh) | 2016-04-08 | 2019-03-01 | 赛伦诺科技有限公司 | 包含丙戊酸的延迟释放药物制剂和其用途 |
-
2014
- 2014-10-08 GB GBGB1417828.9A patent/GB201417828D0/en not_active Ceased
-
2015
- 2015-10-08 MY MYPI2017701203A patent/MY192055A/en unknown
- 2015-10-08 KR KR1020177011492A patent/KR20170063857A/ko not_active Application Discontinuation
- 2015-10-08 CN CN202211237344.5A patent/CN115721635A/zh active Pending
- 2015-10-08 HU HUE15790632A patent/HUE058316T2/hu unknown
- 2015-10-08 ES ES15790632T patent/ES2913225T3/es active Active
- 2015-10-08 WO PCT/GB2015/052950 patent/WO2016055797A2/en active Application Filing
- 2015-10-08 US US15/517,229 patent/US10111845B2/en active Active
- 2015-10-08 SG SG11201702058XA patent/SG11201702058XA/en unknown
- 2015-10-08 RU RU2017114933A patent/RU2732761C2/ru active
- 2015-10-08 AU AU2015329795A patent/AU2015329795B2/en active Active
- 2015-10-08 EP EP15790632.2A patent/EP3203997B1/en active Active
- 2015-10-08 CA CA3234641A patent/CA3234641A1/en active Pending
- 2015-10-08 PL PL15790632T patent/PL3203997T3/pl unknown
- 2015-10-08 EP EP21216908.0A patent/EP4066825A1/en active Pending
- 2015-10-08 CN CN202211231367.5A patent/CN115581691A/zh active Pending
- 2015-10-08 BR BR112017007144A patent/BR112017007144A2/pt not_active Application Discontinuation
- 2015-10-08 CA CA2964041A patent/CA2964041C/en active Active
- 2015-10-08 DK DK15790632.2T patent/DK3203997T3/da active
- 2015-10-08 JP JP2017538468A patent/JP6787901B2/ja active Active
- 2015-10-08 MX MX2017004558A patent/MX2017004558A/es unknown
- 2015-10-08 NZ NZ730307A patent/NZ730307A/en unknown
- 2015-10-08 IL IL251142A patent/IL251142B/en unknown
- 2015-10-08 CN CN201580055071.4A patent/CN107205975A/zh active Pending
-
2017
- 2017-04-06 MX MX2022007221A patent/MX2022007221A/es unknown
- 2017-04-07 CL CL2017000866A patent/CL2017000866A1/es unknown
-
2018
- 2018-09-19 US US16/135,639 patent/US11400064B2/en active Active
-
2020
- 2020-10-29 JP JP2020181522A patent/JP7305605B2/ja active Active
-
2022
- 2022-08-01 US US17/816,486 patent/US20220401393A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112017007144A2 (pt) | ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição. | |
BR112017004704A2 (pt) | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo | |
BR112017007072A2 (pt) | compostos de triazolopiridina e métodos para o tratamento de fibrose cística | |
WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
BR112016027041A8 (pt) | combinações farmacêuticas para tratamento do câncer | |
BR112016015236A8 (pt) | composto,composição farmacêutica,uso de um composto,método de inibição e método para tratar ou aliviar a gravidade de uma doença. | |
BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
BR112017018092A2 (pt) | composto, composição farmacêutica, e, método para tratar e/ou prevenir uma doença ou distúrbio. | |
MX2017004618A (es) | Inhibidores de la biosintesis de sulfato de heparano para el tratamiento de enfermedades. | |
AR101740A1 (es) | Terapia de combinación y composiciones | |
BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
BR112017015852A2 (pt) | forma de cristal, sal hemicálcico, sal hemicálcico di-hidratado, sal monossódico hidratado, sal bissódico monoidratado, sal monossódico anidro e método para preparar o composto 1 | |
PH12018500762A1 (en) | Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
MX2021009806A (es) | Ésteres de ácidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y métodos para usar los mismos. | |
BR112017026535A2 (pt) | composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto | |
BR112017016084A2 (pt) | composição e método para o tratamento da doença veno-oclusiva hepática | |
BR112017018328A2 (pt) | anticorpo de ligação ao tfpi, método para produzir e composição compreendendo o mesmo | |
TW201613578A (en) | Pharmaceutical combinations | |
BR112017005242A2 (pt) | composto, composição farmacêutica, e, composto para uso. | |
BR112017015576A2 (pt) | método para o tratamento de câncer, artigo, método para monitorizar, método para a otimização da eficácia terapêutica, método para a identificação de um biomarcador, utilização, combinação terapêutica, combinação para a utilização e produto | |
BR112017007138A2 (pt) | composto, medicamento, métodos para reduzir proteína 4 de ligação ao retinol e para a profilaxia ou o tratamento de degeneração macular e/ou uma doença, e, uso de um composto. | |
BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
BR112017020053A2 (pt) | novo composto heterocíclico, método para a preparação do mesmo e composição farmacêutica compreendendo o mesmo | |
BR112018004249A2 (pt) | composto, e, composição para prevenção ou tratamento de doenças trombóticas. | |
BR112018002763A2 (pt) | método para cicatrização de ferimentos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |